Ligand id: 7999

Name: sarilumab

Immunopharmacology Comments
In clinical trial sarilumab significantly reduced the signs and symptoms of RA and improved physical function [1-2,4]. A notable side-effect is immune suppression leading to susceptibility to infection.
Immunopharmacology Disease
Disease X-Refs Comment References
Rheumatoid arthritis Disease Ontology: DOID:7148
OMIM: 180300
FDA approved therapeutic for RA (May 2017).
Ankylosing spondylitis Disease Ontology: DOID:7147
Clinical trial in ankylosing spondylitis was terminated.
Uveitis Disease Ontology: DOID:13141
Completed Phase 2 clinical trial for non-infectious uveitis (see NCT01900431).